The FMBA announced the timing of post-registration studies of the vaccine "Konvasel"

“A project plan for the third phase of clinical trials of the Konvasel vaccine is being developed, the study itself is expected to begin at the end of this summer,” RIA Novosti reports.

The studies will evaluate the safety, immunogenicity and preventive efficacy of the vaccine.

Observations will continue for at least six months.

On March 18, the Russian Ministry of Health registered the Konvasel coronavirus vaccine developed by the FMBA.

The head of the FMBA, Veronika Skvortsova, said that among those who were vaccinated with the Konvasel coronavirus vaccine as part of clinical trials, no one fell ill with COVID-19.

According to studies, the vaccine is well tolerated and does not cause allergies.